Aardvark Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Aardvark Therapeutics, Inc. Common Stock (AARD) has an Asset Resilience Ratio of 65.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial flexibility index of Aardvark Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Aardvark Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Aardvark Therapeutics, Inc. Common Stock (AARD) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Aardvark Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Aardvark Therapeutics, Inc. Common Stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $87.06 Million | 65.35% |
| Total Liquid Assets | $87.06 Million | 65.35% |
Asset Resilience Insights
- Very High Liquidity: Aardvark Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 65.35% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aardvark Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Aardvark Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Aardvark Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.51% | $12.02 Million | $77.51 Million | +13.10pp |
| 2023-12-31 | 2.41% | $254.00K | $10.54 Million | -0.85pp |
| 2022-12-31 | 3.26% | $546.00K | $16.76 Million | -- |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more